BMJ《SGLT-2抑制剂用于成人慢性肾脏病患者临床实践指南》解读OA

The clinical practice guideline on the use of sodium-glucose cotransporter 2(SGLT-2)inhibitors in adult patients with chronic kidney disease(CKD),published in the BMJ in October 2024,stratifies patients with CKD into four risk tiers-low,moderate,high,and very high-based on estimated glomerular filtration rate(eGFR)and proteinuria levels to assess their risk of complications and disease progression.The guideline provides a quantitative evaluation of the benefits and risks of SGLT-2 inhibitors across different risk tiers and proposes a tiered recommendation strategy.For instance,for adult patients with CKD who have a low or moderate risk of disease progression and complications,the use of SGLT-2 inhibitors can be considered(weak recommendation);whereas for those with a high or very high risk,the use of SGLT-2 inhibitors is recommended(strong recommendation).This approach supports individualized decision-making for patients and assists general practitioners in the rational and standardized use of SGLT-2 inhibitors across diverse clinical settings.Additionally,the guideline's rapid-access web version offers highly visualized evidence and recommendation presentation tools,facilitating quick reference for general practitioners and supporting the implementation of shared decision-making between clinicians and patients.